BRPI0911035B8 - ativadores de pirrolidinona glicoquinase - Google Patents

ativadores de pirrolidinona glicoquinase

Info

Publication number
BRPI0911035B8
BRPI0911035B8 BRPI0911035A BRPI0911035A BRPI0911035B8 BR PI0911035 B8 BRPI0911035 B8 BR PI0911035B8 BR PI0911035 A BRPI0911035 A BR PI0911035A BR PI0911035 A BRPI0911035 A BR PI0911035A BR PI0911035 B8 BRPI0911035 B8 BR PI0911035B8
Authority
BR
Brazil
Prior art keywords
pyrrolidinone
glycokinase activators
glycokinase
activators
compounds
Prior art date
Application number
BRPI0911035A
Other languages
English (en)
Inventor
Wright Tilley Jefferson
A Brinkman John
Apostle Mcdermott Lee
Haynes Nancy-Ellen
Robert Scott Nathan
Sarabu Ramakanth
Francis Kester Robert
Joseph Berthel Steven
Hayden Stuart
Qian Yimin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0911035A2 publication Critical patent/BRPI0911035A2/pt
Publication of BRPI0911035B1 publication Critical patent/BRPI0911035B1/pt
Publication of BRPI0911035B8 publication Critical patent/BRPI0911035B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

ativadores de pirrolidinona glicoquinase. são proporcionados compostos da fórmula (i): em que x, r1, r2 e r3 são conforme definidos no relatório descritivo, bem como sais farmaceuticamente aceitáveis destes. esses compostos e as composições farmacêuticas contendo os mesmos são úteis no tratamento de doenças ou distúrbios metabólicos tais como, por exemplo, diabetes melito tipo it.
BRPI0911035A 2008-04-16 2009-04-06 ativadores de pirrolidinona glicoquinase BRPI0911035B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4537008P 2008-04-16 2008-04-16
US61/045,370 2008-04-16
US14576109P 2009-01-20 2009-01-20
US61/145,761 2009-01-20
PCT/EP2009/054067 WO2009127546A1 (en) 2008-04-16 2009-04-06 Pyrrolidinone glucokinase activators

Publications (3)

Publication Number Publication Date
BRPI0911035A2 BRPI0911035A2 (pt) 2019-07-16
BRPI0911035B1 BRPI0911035B1 (pt) 2021-03-02
BRPI0911035B8 true BRPI0911035B8 (pt) 2021-05-25

Family

ID=40785354

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911035A BRPI0911035B8 (pt) 2008-04-16 2009-04-06 ativadores de pirrolidinona glicoquinase

Country Status (25)

Country Link
US (1) US7741327B2 (pt)
EP (1) EP2274297B1 (pt)
JP (1) JP5518838B2 (pt)
KR (1) KR101259249B1 (pt)
CN (1) CN102007118B (pt)
AR (1) AR071474A1 (pt)
AT (1) ATE557017T1 (pt)
AU (1) AU2009237794B2 (pt)
BR (1) BRPI0911035B8 (pt)
CA (1) CA2720524C (pt)
CL (1) CL2009000889A1 (pt)
CY (1) CY1112921T1 (pt)
DK (1) DK2274297T3 (pt)
ES (1) ES2386192T3 (pt)
HR (1) HRP20120589T1 (pt)
IL (1) IL207503A (pt)
MX (1) MX2010011226A (pt)
PE (1) PE20091842A1 (pt)
PL (1) PL2274297T3 (pt)
PT (1) PT2274297E (pt)
RU (1) RU2010146384A (pt)
SI (1) SI2274297T1 (pt)
TW (1) TW200944519A (pt)
WO (1) WO2009127546A1 (pt)
ZA (1) ZA201006159B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
US20120142705A1 (en) * 2010-12-06 2012-06-07 Robert Francis Kester Isatin and oxindole compounds
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6297590B2 (ja) * 2012-12-25 2018-03-20 ファ・メディシンＨｕａ Ｍｅｄｉｃｉｎｅ １−（［１，３］ジオキソラン−４−イルメチル）−１ｈ−ピラゾール−３−イルアミンを調製するための方法
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
EP3556354A4 (en) * 2016-12-15 2020-07-01 Hua Medicine (Shanghai) Ltd. ORAL PRODUCTION OF A GLUCOKINASE ACTIVATOR AND PRODUCTION METHOD THEREFOR
US20200095241A1 (en) 2016-12-22 2020-03-26 Bayer Cropscience Aktiengesellschaft Substituted 1,2,4-thiadiazolylpyrrolones and 1,2,4-thiadiazolylhydantoins and salts thereof and use thereof as herbicides
US20200079765A1 (en) 2016-12-22 2020-03-12 Bayer Cropscience Aktiengesellschaft Substituted heteroaryl pyrrolones and salts thereof and use thereof as herbicidal active substances
AU2018391579A1 (en) 2017-12-19 2020-08-06 Bayer Aktiengesellschaft Substituted N-heterocyclyl- and N-heteroaryl-tetrahydropyrimidinones and the salts thereof, and the use of same as herbicidal active substances
AU2019278016A1 (en) * 2018-05-31 2021-01-21 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and DPP‐IV inhibitor, and preparation method and use thereof
AU2020443475A1 (en) * 2020-04-22 2022-11-17 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
US11813274B2 (en) 2020-04-22 2023-11-14 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
CN114712488B (zh) * 2021-01-04 2023-12-26 华领医药技术（上海）有限公司 Dorzagliatin和胰高血糖素样肽-1类似物的药物组合物
CN113527265B9 (zh) * 2021-02-02 2022-07-19 湖南南新制药股份有限公司 一种氘代吡咯烷酮衍生物、药物组合物及其用途
CN113750100B (zh) * 2021-08-31 2022-12-30 海南中济医药科技有限公司 一种含有多扎格列艾汀与西格列汀的药物组合物及其制备方法
AR127064A1 (es) 2021-09-15 2023-12-13 Hua Medicine Shanghai Ltd Prodroga de derivados de pirrolidona como activador de glucoquinasa

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE842346C (de) 1950-10-14 1952-06-26 Joachim Dipl-Chem Dr Goerdeler Verfahren zur Darstellung von 5-Amino-1, 2, 4-thiodiazolen
DK496784A (da) 1983-10-18 1985-04-19 Du Pont 8-substituerede pyrazolopentathiepiner og dermed beslaegtede forbindelser
JPS6284064A (ja) 1985-10-09 1987-04-17 Shionogi & Co Ltd ３−パ−フルオロアルキル−５−ヒドロキシイソオキサゾ−ル類
CH668422A5 (de) 1986-06-26 1988-12-30 Lonza Ag 4-benzyloxy-3-pyrrolin-2-on, dessen herstellung und verwendung zur synthese von tetramsaeure.
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
IL116507A (en) 1991-11-13 1997-08-14 Schering Ag Pyrazole derivatives
US5498190A (en) 1994-06-27 1996-03-12 Handsontoys, Inc. Flexible foam construction toy and method of manufacturing same
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
DE69910762T2 (de) 1998-04-30 2004-03-11 Agouron Pharmaceuticals, Inc., La Jolla Antipicornavirale verbindungen, deren herstellung und verwendung
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
DK1169312T3 (da) 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
ATE250053T1 (de) 1999-07-15 2003-10-15 Pharmacopeia Inc Bradikinin b1 rezeptor antagonisten
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
BR0110573A (pt) 2000-05-03 2003-04-01 Hoffmann La Roche Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
ES2230309T3 (es) 2000-05-08 2005-05-01 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa.
AU2001265914B2 (en) 2000-05-08 2005-11-03 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
BR0115999A (pt) 2000-12-06 2003-09-30 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE60309856T2 (de) * 2002-04-26 2007-06-14 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
CN101805358A (zh) 2002-10-03 2010-08-18 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑-2-基)酰胺或磺酰胺
AU2003287038A1 (en) 2002-10-09 2004-05-04 The Board Of Trustees Of The University Of Illinois METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO (2, 3-b) FURAN AND RELATED COMPOUNDS
US7132425B2 (en) * 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (en) 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
CN101712657A (zh) 2003-02-26 2010-05-26 万有制药株式会社 杂芳基氨基甲酰基苯衍生物
CA2547591C (en) 2003-10-24 2010-08-17 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
MXPA06004647A (es) 2003-10-27 2006-06-27 Merck & Co Inc Sal antagonista de ccr-2.
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
AU2005214137B2 (en) 2004-02-18 2008-05-29 Astrazeneca Ab Compounds
AU2005214132B9 (en) 2004-02-18 2009-06-25 Astrazeneca Ab Benzamide derivatives and their use as glucokinae activating agents
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
CN101098876A (zh) 2004-04-02 2008-01-02 诺瓦提斯公司 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
BRPI0510163A (pt) 2004-04-21 2007-10-02 Prosidion Ltd compostos de amidas tri(ciclo)-substituìdas
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
BRPI0514147A (pt) 2004-08-12 2008-05-27 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
WO2006094770A2 (en) 2005-03-08 2006-09-14 Ludwig-Maximilians-Universitaet Muenchen Apparatus and method for the final processing of a forming tool for a sheet-metal body part
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
JP2009500442A (ja) 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
NZ575513A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
AR057661A1 (es) 2005-07-11 2007-12-12 Tanabe Seiyaku Co Un derivado de oxima y sus preparaciones
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
WO2007026761A1 (ja) 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
CA2627892A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
CA2628486A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd. Tricyclo substituted amides
JP2009514835A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
CN101437512A (zh) 2006-01-27 2009-05-20 阿雷生物药品公司 葡萄糖激酶活化剂
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
NZ571997A (en) 2006-03-24 2011-08-26 Array Biopharma Inc 2 -aminopyridine analogs as glucokinase activators
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
EP2463283B1 (en) 2006-04-20 2014-06-11 Pfizer Products Inc. Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
EP2019824A2 (en) 2006-04-28 2009-02-04 Transtech Pharma, Inc. Benzamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
MX2009000688A (es) 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
EP2049103A2 (en) * 2006-07-26 2009-04-22 Novartis AG Inhibitors of undecaprenyl pyrophosphate synthase
EP2116533B1 (en) 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008132142A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
CN101121688A (zh) 2007-09-14 2008-02-13 南开大学 合成奥拉西坦的改进方法

Also Published As

Publication number Publication date
CA2720524C (en) 2016-07-12
IL207503A (en) 2014-03-31
RU2010146384A (ru) 2012-05-27
AU2009237794B2 (en) 2014-07-10
BRPI0911035A2 (pt) 2019-07-16
CL2009000889A1 (es) 2010-07-19
MX2010011226A (es) 2010-11-01
ATE557017T1 (de) 2012-05-15
ES2386192T3 (es) 2012-08-13
SI2274297T1 (sl) 2012-08-31
PL2274297T3 (pl) 2012-10-31
JP5518838B2 (ja) 2014-06-11
WO2009127546A1 (en) 2009-10-22
PE20091842A1 (es) 2009-12-04
BRPI0911035B1 (pt) 2021-03-02
EP2274297B1 (en) 2012-05-09
IL207503A0 (en) 2010-12-30
KR20100123912A (ko) 2010-11-25
US7741327B2 (en) 2010-06-22
CA2720524A1 (en) 2009-10-22
PT2274297E (pt) 2012-06-20
AU2009237794A1 (en) 2009-10-22
KR101259249B1 (ko) 2013-04-30
CN102007118B (zh) 2014-12-31
ZA201006159B (en) 2011-05-25
TW200944519A (en) 2009-11-01
HRP20120589T1 (hr) 2012-08-31
CN102007118A (zh) 2011-04-06
AR071474A1 (es) 2010-06-23
EP2274297A1 (en) 2011-01-19
CY1112921T1 (el) 2016-04-13
JP2011517692A (ja) 2011-06-16
US20090264445A1 (en) 2009-10-22
DK2274297T3 (da) 2012-07-16

Similar Documents

Publication Publication Date Title
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
SV2011003855A (es) Heteroarilos sustituidos
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
MX2010009922A (es) Activadores de piridazinona glucocinasa.
EA201170772A1 (ru) Органические соединения
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
BRPI0811280B8 (pt) compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
MY149622A (en) Pyrazoles as 11-beta-hsd-1
BRPI0915592A2 (pt) composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii
UY30759A1 (es) Compuestos quimicos
MY153258A (en) Pyrazinone derivatives and their use inthe threatment of lung diseases
BR112014009717A2 (pt) "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica"
EA201100503A1 (ru) Глюкозидные производные и их применения
MY155517A (en) Heterocyclic derivatives
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BR112013002957A2 (pt) composto de 1,4,5,6-tetrahidro-pirimidin-2-ilamina
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
BR112012006387A2 (pt) aminas de triazol fundidas como moduladores de p2x7
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
BRPI0924617A8 (pt) Compostos heterociclicos de fenoximetila
MX367131B (es) Sales de xantilio 3,6-disustituidas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF